Overview

To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol

Status:
Completed

Trial end date:
2002-11-01

Target enrollment:

Participant gender:

Summary

The study aims to compare blood and urine concentrations of mirabegron (YM178) in healthy poor or extensive metabolizers for CYP2D6 and to evaluate if blood levels of metoprolol change whilst being dosed at the same time with daily miragebron.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Metoprolol
Mirabegron